AUSTRALIA MPL AU Price (at 05:10, 18 Mar 2016 GMT) Outperform A$2.74 Valuation A$ 2.89 - DCF (WACC 8.3%, beta 0.9, ERP 5., RFR 3.8%, TGR 3.) 12-month target A$ 2.88 12-month TSR % +8.9 Volatility Index Low/Medium GICS sector Insurance Market cap A$m 7,546 30-day avg turnover A$m 39.4 Number shares on issue m 2,754 Investment fundamentals Year end 30 Jun 2015A 2016E 2017E 2018E NEP m 0.0 0.0 0.0 0.0 Underwriting Result m 0.0 0.0 0.0 0.0 Investment Income m 0.0 0.0 0.0 0.0 Reported profit m 291.8 409.2 372.7 355.8 Net Op Income m 291.8 409.2 372.7 355.8 EPS adj 10.6 14.9 13.5 12.9 PER adj x 25.9 18.4 20.2 21.2 PER rel x 1.66 1.11 1.38 1.56 DPS 5.3 10.6 9.8 9.3 Dividend yield % 1.9 3.9 3.6 3.4 Franking % 100 100 100 100 Total SH Funds m 1,442.0 1,564.1 1,662.6 1,728.8 BV/S 52.4 56.8 60.4 62.8 ROE % 20.2 27.2 23.1 21.0 ROA % 9.3 13.3 12.1 11.1 P/BV x 5.2 4.8 4.5 4.4 MPL AU vs ASX 100, & rec history Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, March 2016 (all figures in AUD unless noted) 21 March 2016 Macquarie Securities (Australia) Limited MPL self help pays off Event Claims review and self help payoff from improved operational performance. Impact MPL s claims growth moderation has improved gross margin and profitability in 1H16. The sector ex MPL has not seen the same positive trends. Claims Growth per policyholder (see Fig. 1): MPL +0.8% in 1H16 vs +4.4% FY13-FY15 & Sector ex MPL +5.7% 1H16 vs +5.7% FY13-FY15. Gross Margin (see Fig. 2): MPL 17.2% in 1H16 vs 13.7% average FY13- FY15 & Sector ex MPL 11.8% in 1H16 vs 12.6% FY13-FY15. MPL s outperformance vs the sector contrasts with BUPA s comments: "Looking forward, [BUPA] anticipate market conditions will remain challenging, particularly in Australia... [with] continued margin pressure in health insurance market, driven by cost of care and intensifying competition". We attribute the moderation in MPL s claims growth to a combination of: 1) increased health fund analytics re product entitlements (incl. fraud detection); 2) increased exclusions; 3) improved hospital contracting; and 4) switching of adverse risks away from MPL (note the Calvary Health Care [11 hospitals in SA, ACT, Wagga & TAS] contract dispute with MPL contributed, as BUPA holds the following market share ~38% Tas, ~53% SA and ~21% ACT). One of the criticisms of the PHI sector is the lack of incentive to invest in claims mitigation given the risk equalisation system shares the benefits across all other health funds. Premiums are community rated, with insurers not able to price for individual risk factors or refuse cover, necessitating a risk equalisation scheme across all funds. We show in this note that larger funds (MPL & BUPA) retain ~69% of savings they achieve despite risk equalisation. This provides the larger funds with greater pay off from self help initiatives. MPL is making the most of this. Earnings and target price revision No change to EPS or Target Price. Note that we upgraded EPS by FY16 +0.9%, FY17 +15., FY18 +3.6% on 2 March 2016. We upgraded to Outperform [from Neutral] on 17 March 2016. Sensitivity to further change in claims growth: +/-100bps change in claims growth with premium growth unchanged equates to EPS changes of +/-1. Price catalyst 12-month price target: A$2.88 based on a DCF methodology. Catalyst: Claims growth trends, Federal budget released in 3 May 2016. Action and recommendation Outperform as: 1) the risk to FY16 earnings are skewed to the upside (MRE forecasts for MPL are ~6% above consensus) as claims growth risk remains to the downside; and 2) regulatory risk is moderating as the time to the 2016 budget and Federal election is shortening. Please refer to page 8 for important disclosures and analyst certification, or on our website www.macquarie.com/research/disclosures.
Dec-08 Jun-09 Dec-09 Jun-10 Dec-10 Jun-11 Dec-11 Jun-12 Dec-12 Jun-13 Dec-13 Jun-14 Dec-14 Jun-15 Dec-15 Macquarie Wealth Management Overview of trends for hospital and ancillary claims Fig 1 Medibank drove the industry wide decline in claims growth (note that we have not split out the nib Health Fund who also saw claims growth below industry at +2. per policyholder [including the benefit from risk equalisation driven by lower MPL claims growth]) Claims Growth 8% 1H16 FY13-15 7% 6% 5.7% 5.3% 5.7% 5% 4.3% 4.4% 4% 3% 2% 1% 0.8% Market MPL Market Ex. MPL Market MPL Market Ex. MPL Source: Company data, APRA, PHIAC, Macquarie Research, March 16 Fig 2 Medibank drove the industry wide improvement in Gross Margins (note that we have not split out the nib Health Fund who also saw gross margin improvement +110bps versus the average FY13-15 [including the benefit to risk equalisation driven by lower MPL claims growth]) Gross Margin 24% 1H16 FY13-15 2 17.2% 16% 12% 13.3% 11.8% 12.9% 13.7% 12.6% 8% 4% Market MPL Market Ex. MPL Market MPL Market Ex. MPL Source: Company data, APRA, PHIAC, Macquarie Research, March 16 Fig 3 Sector Hospital & Ancillary claims continued to contract through December 2015 driven by MPL and nib claims performance PHI Benefits growth (rolling 12m) 14% 12% 1 8% 6% 4% 2% Hospital - 12m Ancillary - 12m Source: APRA, PHIAC, Macquarie Research, March 16 21 March 2016 2
Jun-04 Dec-04 Jun-05 Dec-05 Jun-06 Dec-06 Jun-07 Dec-07 Jun-08 Dec-08 Jun-09 Dec-09 Jun-10 Dec-10 Jun-11 Dec-11 Jun-12 Dec-12 Jun-13 Dec-13 Jun-14 Dec-14 Jun-15 Dec-15 Dec-02 Dec-03 Dec-04 Dec-05 Dec-06 Dec-07 Dec-08 Dec-09 Dec-10 Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-04 Jun-05 Dec-05 Jun-06 Dec-06 Jun-07 Dec-07 Jun-08 Dec-08 Jun-09 Dec-09 Jun-10 Dec-10 Jun-11 Dec-11 Jun-12 Dec-12 Jun-13 Dec-13 Jun-14 Dec-14 Jun-15 Dec-15 Macquarie Wealth Management Fig 4 Moderating utilisation, reduced penetration and lower benefits per episode are all contributing to a moderation in hospital benefits growth... Growth in Hospital Benefits (ann. ave) 14% 12% 1 8% 6% 4% 2% -2% Volume (population growth) Volume (penetration) Inflation (benefits per episode) Utilisation (episodes per insured person) Other Total Source: APRA, PHIAC, Macquarie Research, March 16 Fig 5 Under 65 year old policyholders are driving the moderation in growth of claims from policyholders (with a smaller decline in 65-79yr old benefits growth) this suggests that the change is somewhat supply induced. Also note the positive trend following the previous low in Dec 2005. Growth in Hospital Benefits (ann. ave) 14% 12% 1 8% 6% 4% 2% 80+ 65-79 50-65 y.o. 30's and 40's Under 30's Total Source: APRA, PHIAC, Macquarie Research, March 16 Fig 6 Moderating growth in utilisation, reduced PHI contribution and penetration continues to drive lower in ancillary claims in December 2015 Ancillary benefits growth 15. 12.5% 10. 7.5% 5. 2.5% 0. -2.5% -5. Ancillary benefits growth 15. 12.5% 10. 7.5% 5. 2.5% 0. -2.5% -5. Population growth Utilisation Change in PHI contribution to ancillary fee Ancillary benefit growth Penetration of Ancillary cover Service Fee inflation Other Source: APRA, PHIAC, Macquarie Research, March 16 21 March 2016 3
Payoff from a focus on claims growth MPL is well placed as the leading private health insurer to improve claims outcomes. Relative to smaller health insurers, MPL has greater incentives to save hospital claims costs under the current risk equalisation regime, retaining almost half of any industry savings generated for over 65 year olds. This compares to smaller funds, which retain around one third of savings in this demographic (refer to the charts following). Rising claims cost for over 65 year olds represents the largest opportunity to reduce claims costs. MPL would retain ~48% of the benefits from any claims cost reduction among this age cohort. This is well in excess of competitors with smaller market share. Fig 7 Medibank retention of total claims costs under current retrospective risk equalisation by age category and large claim pool Age % of Hospital claims Risk Eqalisation Non-Risk Equalisation component Risk Equalisation component Total 0-54 31. 0. 100. 0. 100. 55-59 7.4% 15. 85. 4.2% 89.2% 60-64 9.8% 43. 57. 12.1% 69.1% 65-69 12.3% 60. 40. 16.9% 56.9% 70-74 12.1% 70. 30. 19.7% 49.7% 75-79 10.9% 76. 24. 21.4% 45.4% 80-84 8.4% 78. 22. 21.9% 43.9% 85+ 7.9% 82. 18. 23. 41. Weighted average - all policyholders 57.4% 12. 69.4% Weighted average - over 65s 28. 20.2% 48.2% Source: Macquarie Analysis of APRA and PHIAC data, March 2016. Fig 8 Retention of total hospital claims costs under current retrospective risk equalisation Benefit - All policyholders 8 69.4% 69. 7 62.8% 12. 11.6% 60.2% 60. 6 5.4% 2.8% 2.6% 5 4 3 57.4% 57.4% 57.4% 57.4% 57.4% 2 1 MPL BUPA HCF nib HBF Claims Costs (Non-Risk Equalisation component) Claims Costs (Risk Equalisation component) Source: Macquarie Analysis of APRA and PHIAC data, March 2016. 21 March 2016 4
Fig 9 Retention of over 65 yr olds hospital claims costs under current retrospective risk equalisation Benefit - Over 65s 8 7 6 5 48.2% 47.6% 4 20.2% 19.7% 37.1% 32.7% 32.4% 3 9.1% 4.7% 4.5% 2 1 28. 28. 28. 28. 28. MPL BUPA HCF nib HBF Claims Costs (Non-Risk Equalisation component) Claims Costs (Risk Equalisation component) Source: Macquarie Analysis of APRA and PHIAC data, March 2016. 21 March 2016 5
Price: $ 2.74 Balance Date: June 30 Private Health Insurance 1H15A 2H15A 1H16A 2H16E FY14A FY15A FY16E FY17E FY18E Premium revenue 2,943.3 2,991.5 3,080.0 3,128.9 5,648.7 5,934.8 6,208.9 6,505.5 6,840.4 Claims -2,535.1-2,557.8-2,551.1-2,621.5-4,884.3-5,092.9-5,172.6-5,468.9-5,819.7 Gross Margin 408.2 433.7 528.9 507.3 764.4 841.9 1,036.2 1,036.7 1,020.7 Management Expenses -234.7-277.9-257.2-266.0-511.1-512.6-523.2-539.1-549.8 Operating Profit 173.5 155.8 271.7 241.4 253.3 329.3 513.1 497.6 471.0 Complementary Services 1H15A 2H15A 1H16A 2H16E FY14A FY15A FY16E FY17E FY18E Revenue 331.5 309.7 300.6 294.2 718.4 641.2 594.8 593.2 602.1 Cost of Sales -263.5-246.1-244.6-239.4-533.8-509.6-484.0-482.7-489.9 Gross Profit 68.0 63.6 56.0 54.8 184.6 131.6 110.8 110.5 112.2 Management Expenses -60.8-56.6-46.8-45.3-151.0-117.4-92.1-93.5-94.9 Operating Profit 7.2 7.0 9.2 9.5 33.6 14.2 18.7 17.1 17.3 Group 1H15A 2H15A 1H16A 2H16E FY14A FY15A FY16E FY17E FY18E Health Insurance premium revenue 2,943.3 2,991.5 3,080.0 3,128.9 5,648.7 5,934.8 6,208.9 6,505.5 6,840.4 Other revenue (Complementary services) 331.5 309.7 300.6 294.2 718.4 641.2 594.8 593.2 602.1 Total Revenue 3,274.8 3,301.2 3,380.6 3,423.1 6,367.1 6,576.0 6,803.7 7,098.7 7,442.6 Net Claims -2,535.1-2,557.8-2,551.1-2,621.5-4,884.3-5,092.9-5,172.6-5,468.9-5,819.7 Cost of Sales (Complementary services) -263.5-246.1-244.6-239.4-533.8-509.6-484.0-482.7-489.9 Gross Profit 476.2 497.3 584.9 562.2 949.0 973.5 1,147.1 1,147.2 1,132.9 Health Insurance Management Expenses -234.7-277.9-257.2-266.0-511.1-512.6-523.2-539.1-549.8 Complementary services Management Expenses -60.8-56.6-46.8-45.3-151.0-117.4-92.1-93.5-94.9 Segment Operating Profit 180.7 162.8 280.9 250.9 286.9 343.5 531.8 514.6 488.3 Corporate Overheads -10.9-12.6-13.6-15.0-31.6-23.5-28.6-29.0-29.5 Operating Profit 169.8 150.2 267.3 235.9 255.3 320.0 503.2 485.6 458.8 Net Investment income 43.4 50.4 18.6 27.3 113.9 93.8 45.9 54.6 57.4 Other income/expense -0.4-7.6-3.7-3.8-8.1-8.0-7.5-7.7-8.0 Profit before tax 212.8 193.0 282.2 259.4 361.1 405.8 541.6 532.5 508.3 Tax expense -61.4-52.6-54.6-77.8-102.6-114.0-132.4-159.7-152.5 Pro-forma Net Profit After Tax 151.4 140.4 227.6 181.6 258.5 291.7 409.2 372.7 355.8 Balance Sheet 1H15A 2H15A 1H16A 2H16E FY14A FY15A FY16E FY17E FY18E Cash and Equiv 471 409 456 597 708 409 597 628 660 Financial Assets 1,426 1,972 1,702 1,588 1,491 1,972 1,588 1,669 1,755 Receivables 302 301 310 362 339 301 362 378 396 DAC 46 68 65 82 38 68 82 83 85 PPE 124 106 99 94 138 106 94 85 76 Intangible assets 253 262 281 281 244 262 281 281 281 Other 24 24 11 11 18 24 11 11 11 Total Assets 2,645 3,141 2,924 3,015 2,974 3,141 3,015 3,135 3,264 Payables 309 419 323 404 346 419 404 420 439 Claims Liabilities 382 411 381 387 407 411 387 407 427 UEP 529 726 557 522 665 726 522 507 531 Other 127 144 138 138 162 144 138 138 138 Total Liabilities 1,346 1,699 1,399 1,451 1,580 1,699 1,451 1,472 1,535 Net Assets 1,299 1,442 1,526 1,564 1,394 1,442 1,564 1,663 1,729 Key ratios 1H15A 2H15A 1H16A 2H16E FY14A FY15A FY16E FY17E FY18E Private Health Insurance: Net Policyholder growth 0.5% 1.3% -2.5% 0.3% 1.5% 0.9% -1.1% 0.6% 0.7% PSEU growth 0.7% 0.7% -0.2% -0.7% 1. 0.9% -0.7% 1.3% 1.3% Premium growth 5.2% 4.9% 4.6% 4.6% 5.7% 5.1% 4.6% 4.8% 5.1% Gross Margin 13.9% 14.5% 17.2% 16.2% 13.5% 14.2% 16.7% 15.9% 14.9% MER 8. 9.3% 8.4% 8.5% 9. 8.6% 8.4% 8.3% 8. Net Margin 5.9% 5.2% 8.8% 7.7% 4.5% 5.5% 8.3% 7.6% 6.9% Complementary Services: Revenue growth -10.1% -11.4% -9.3% -5. 41.6% -10.7% -7.2% -0.3% 1.5% Revenue growth - ex Immigration contract 0. -3.2% -8.4% -5. 49.5% -1.6% -6.8% -0.3% 1.5% Gross Profit Margin 20.5% 20.5% 18.6% 18.6% 25.7% 20.5% 18.6% 18.6% 18.6% Operating Profit Margin 2.2% 2.3% 3.1% 3.2% 4.7% 2.2% 3.1% 2.9% 2.9% Operating Profit Margin - ex immigration contract 2. 2.2% 3.1% 3.2% 1.8% 2.1% 3.1% 2.9% 2.9% Group: EPS 5.5 5.1 8.3 6.6 9.39 10.60 14.86 13.53 12.92 DPS 0.0 5.3 5.0 5.6 0.00 5.30 10.60 9.80 9.30 EPS growth 50.3% 29.3% 6. 12.9% 40.2% -8.9% -4.5% PER (x) 24.8 26.9 16.6 20.8 32.0 25.8 18.4 20.2 21.2 Dividend Yield 0. 3.9% 3.6% 4.1% 0. 1.9% 3.9% 3.6% 3.4% Franking n/a 100. 100. 100. n/a 100. 100. 100. 100. ROE 23.4% 20.5% 30.7% 23.5% 15.9% 19.7% 27.2% 23.1% 21. Revenue growth 3.4% 3.1% 3.2% 3.7% 8.8% 3.3% 3.5% 4.3% 4.8% Revenue growth ex Immigration 4.7% 4.1% 3.3% 3.7% 9. 4.4% 3.5% 4.3% 4.8% Gross Profit Margin 14.5% 15.1% 17.3% 16.4% 14.9% 14.8% 16.9% 16.2% 15.2% Operating Profit Margin 5.2% 4.5% 7.9% 6.9% 4. 4.9% 7.4% 6.8% 6.2% Operating Profit Margin - ex immigration contract 5.2% 4.5% 7.9% 6.9% 3.7% 4.9% 7.4% 6.8% 6.2% NPAT growth 10.8% 15.2% 50.3% 29.3% 6. 12.9% 40.2% -8.9% -4.5% Underlying NPAT growth 20.3% 26.4% 50.9% 29.4% 2.4% 26.1% 38.3% -8.9% -4.5% Valuation Valuation as at today 7,616 Capital return 5.3% PER at Current share price (1yr fwd) 18.44 Valuation in 12m time 7,948 Dividend Yield 3.9% PER at Price Target (2yr fwd) 21.81 Number of shares 2,754 Share price target (12m) 2.88 Total Return 9.2% Dividend Yield at Price Target (2yr fwd) 3.3% Source: Company Data, Macquarie Research, March 2016. 21 March 2016 6
Fundamentals Macquarie Wealth Management Macquarie Quant View The quant model currently holds a strong positive view on Medibank Private. The strongest style exposure is Earnings Momentum, indicating this stock has received earnings upgrades and is well liked by sell side analysts. The weakest style exposure is Valuations, indicating this stock is over-priced in the market relative to its peers. 33/247 Global rank in Insurance % of BUY recommendations 27% (4/15) Number of Price Target downgrades 3 Number of Price Target upgrades 9 Attractive Quant Local market rank Global sector rank Displays where the company s ranked based on the fundamental consensus Price Target and Macquarie s Quantitative Alpha model. Two rankings: Local market (Australia & NZ) and Global sector (Insurance) Macquarie Alpha Model ranking A list of comparable companies and their Macquarie Alpha model score (higher is better). Factors driving the Alpha Model For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score. 1.2 NIB Holdings 0.8 NIB Holdings Japara Healthcare 0.7 Japara Healthcare Ramsay Health Care 0.4 Ramsay Health Care Regis Healthcare 0.0 Regis Healthcare Insurance Australia Group -0.3 Insurance Australia Group Healthscope -1.0 Healthscope -3.0-2.0-1.0 0.0 1.0 2.0 3.0-10 -8-6 -4-2 2 4 6 8 10 Valuations Growth Profitability Earnings Momentum Price Momentum Quality Macquarie Earnings Sentiment Indicator The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below. Drivers of Stock Return Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple. NIB Holdings Japara Healthcare Ramsay Health Care Regis Healthcare Insurance Australia Group Healthscope 0.6 0.8 0.2 0.2-0.1 0.7 1.5 NIB Holdings Japara Healthcare Ramsay Health Care Regis Healthcare Insurance Australia Group Healthscope -3.0-2.0-1.0 0.0 1.0 2.0 3.0-5 -4-3 -2-1 1 2 3 4 5 Dividend Return Multiple Return Earnings Outlook 1Yr Total Return How it looks on the Alpha model A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market. Alpha Model Score Valuation Growth Profitability Earnings Momentum Price Momentum Quality Capital & Funding Liquidity Risk Technicals & Trading Normalized Score 1.20-0.03 0.29 0.38 0.85 0.33 0.84 0.12-0.61 0.52 0.66 Percentile relative to sector(/247) Percentile relative to market(/393) 0 50 100 0 50 100 0 0 1 1 Source (all charts): FactSet, Thomson Reuters, and Macquarie Research. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (cpg@macquarie.com) 21 March 2016 7
Important disclosures: Recommendation definitions Macquarie - Australia/New Zealand Outperform return >3% in excess of benchmark return Neutral return within 3% of benchmark return Underperform return >3% below benchmark return Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield Macquarie Asia/Europe Outperform expected return >+1 Neutral expected return from -1 to +1 Underperform expected return <-1 Macquarie South Africa Outperform expected return >+1 Neutral expected return from -1 to +1 Underperform expected return <-1 Macquarie - Canada Outperform return >5% in excess of benchmark return Neutral return within 5% of benchmark return Underperform return >5% below benchmark return Macquarie - USA Outperform (Buy) return >5% in excess of Russell 3000 index return Neutral (Hold) return within 5% of Russell 3000 index return Underperform (Sell) return >5% below Russell 3000 index return Volatility index definition* This is calculated from the volatility of historical price movements. Very high highest risk Stock should be expected to move up or down 60 10 in a year investors should be aware this stock is highly speculative. High stock should be expected to move up or down at least 40 6 in a year investors should be aware this stock could be speculative. Medium stock should be expected to move up or down at least 30 4 in a year. Low medium stock should be expected to move up or down at least 25 3 in a year. Low stock should be expected to move up or down at least 15 25% in a year. * Applicable to Asia/Australian/NZ/Canada stocks only Recommendations 12 months Note: Quant recommendations may differ from Fundamental Analyst recommendations Financial definitions All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests EPS = adjusted net profit / efpowa* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards). Recommendation proportions For quarter ending 31 December 2015 AU/NZ Asia RSA USA CA EUR Outperform 50.68% 61.04% 53.16% 47.9 65.22% 43.59% (for global coverage by Macquarie, 5.33% of stocks followed are investment banking clients) Neutral 31.51% 24.66% 34.18% 47.7 29.71% 34.62% (for global coverage by Macquarie, 5.02% of stocks followed are investment banking clients) Underperform 17.81% 14.3 12.66% 4.39% 5.07% 21.79% (for global coverage by Macquarie, 3.78% of stocks followed are investment banking clients) MPL AU vs ASX 100, & rec history (all figures in AUD currency unless noted) Note: Recommendation timeline if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, March 2016 12-month target price methodology MPL AU: A$2.88 based on a DCF methodology Company-specific disclosures: MPL AU: MACQUARIE EQUITIES LIMITED or one of its affiliates managed or co-managed a public offering of securities of Ltd in the past 24 months, for which it received compensation. MACQUARIE EQUITIES NEW ZEALAND LIMITED or one of its affiliates managed or co-managed a public offering of securities of Ltd in the past 24 months, for which it received compensation. Macquarie and its affiliates collectively and beneficially own or control 1% or more of any class of Limited's equity securities. MACQUARIE CAPITAL (AUSTRALIA) LIMITED or one of its affiliates managed or co-managed a public offering of securities of Ltd in the past 24 months, for which it received compensation. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures. Date Stock Code (BBG code) Recommendation Target Price 02-Mar-2016 MPL AU Neutral A$2.88 20-Feb-2016 MPL AU Neutral A$2.82 22-Jan-2016 MPL AU Neutral A$2.72 09-Sep-2015 MPL AU Outperform A$2.65 21-Aug-2015 MPL AU Outperform A$2.66 28-May-2015 MPL AU Outperform A$2.65 20-Feb-2015 MPL AU Outperform A$2.72 05-Jan-2015 MPL AU Outperform A$2.62 Target price risk disclosures: MPL AU: The PHI sector in Australia is highly regulated. MPL does not control the enactment or content of new legislation and regulations. Product design and inadequate premium rate approvals may impact the net margin that MPL s PHI products generate. Complementary Services operations are subject to contract execution and renewal risk. IT renewal: MPL is undertaking a major IT project to replace its core policy and CRM systems. Failure to deliver the project as expected could impact performance. Analyst certification: Analyst certification: We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Limited (MGL) total revenues, a portion of which are generated by Macquarie Group s Investment Banking activities. 21 March 2016 8
General disclosure: This research has been issued by Macquarie Securities (Australia) Limited ABN 58 002 832 126, AFSL 238947, a Participant of the ASX and Chi-X Australia Pty Limited. This research is distributed in Australia by Macquarie Wealth Management, a division of Macquarie Equities Limited ABN 41 002 574 923 AFSL 237504 ("MEL"), a Participant of the ASX, and in New Zealand by Macquarie Equities New Zealand Limited ( MENZ ) an NZX Firm. Macquarie Private Wealth s services in New Zealand are provided by MENZ. Macquarie Bank Limited (ABN 46 008 583 542, AFSL No. 237502) ( MBL ) is a company incorporated in Australia and authorised under the Banking Act 1959 (Australia) to conduct banking business in Australia. None of MBL, MGL or MENZ is registered as a bank in New Zealand by the Reserve Bank of New Zealand under the Reserve Bank of New Zealand Act 1989. Apart from Macquarie Bank Limited ABN 46 008 583 542 (MBL), any MGL subsidiary noted in this research,, is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Australia) and that subsidiary s obligations do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of that subsidiary, unless noted otherwise. This research contains general advice and does not take account of your objectives, financial situation or needs. Before acting on this general advice, you should consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision. This research has been prepared for the use of the clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. This research is based on information obtained from sources believed to be reliable, but the Macquarie Group does not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. The Macquarie Group accepts no liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. The Macquarie Group produces a variety of research products, recommendations contained in one type of research product may differ from recommendations contained in other types of research. The Macquarie Group has established and implemented a conflicts policy at group level, which may be revised and updated from time to time, pursuant to regulatory requirements; which sets out how we must seek to identify and manage all material conflicts of interest. The Macquarie Group, its officers and employees may have conflicting roles in the financial products referred to in this research and, as such, may effect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case. The Macquarie Group s employees or officers may provide oral or written opinions to its clients which are contrary to the opinions expressed in this research. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures Macquarie Group We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group s Investment Banking activities. General disclaimers: Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Country-specific disclaimers: Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered brokerdealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-a share research is distributed into Mainland China by Macquarie Capital 21 March 2016 9
Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), formerly known as Macquarie Capital (India) Pvt. Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai-iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xpath=/wq/fundmgr/disfundmgranalyststut.xml&divisionid=mdis03002001000000&serviceid=sdis03002 001000. South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-us affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc. s affiliate s analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. Macquarie Group 21 March 2016 10